JP2025148550A5 - - Google Patents
Info
- Publication number
- JP2025148550A5 JP2025148550A5 JP2025120522A JP2025120522A JP2025148550A5 JP 2025148550 A5 JP2025148550 A5 JP 2025148550A5 JP 2025120522 A JP2025120522 A JP 2025120522A JP 2025120522 A JP2025120522 A JP 2025120522A JP 2025148550 A5 JP2025148550 A5 JP 2025148550A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- concentration
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828859P | 2019-04-03 | 2019-04-03 | |
| US62/828,859 | 2019-04-03 | ||
| US201962832032P | 2019-04-10 | 2019-04-10 | |
| US62/832,032 | 2019-04-10 | ||
| JP2021558657A JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸2-スルファターゼを含むタンパク質分子の製剤 |
| PCT/US2020/026669 WO2020206320A1 (en) | 2019-04-03 | 2020-04-03 | Formulations of protein molecules comprising iduronate 2-sulfatase |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Division JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸2-スルファターゼを含むタンパク質分子の製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025148550A JP2025148550A (ja) | 2025-10-07 |
| JP2025148550A5 true JP2025148550A5 (cg-RX-API-DMAC7.html) | 2026-05-21 |
Family
ID=70457135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Active JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸2-スルファターゼを含むタンパク質分子の製剤 |
| JP2025120522A Pending JP2025148550A (ja) | 2019-04-03 | 2025-07-17 | イズロン酸2-スルファターゼを含むタンパク質分子の製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Active JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸2-スルファターゼを含むタンパク質分子の製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12667606B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3947661A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7715635B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220004651A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113785054A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020252554B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019520A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134538A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA71657A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011612A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020206320A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| EP3699923A1 (de) * | 2019-02-20 | 2020-08-26 | Fresenius Medical Care Deutschland GmbH | Absicherungsmechanismus fuer den betrieb von medizinischen geraeten unter verwendung von verbrauchsgegenstaenden im umfeld einer dialyse |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| US20250018015A1 (en) | 2021-07-23 | 2025-01-16 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| KR20230134822A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제 |
| TW202542190A (zh) * | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物 |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| EP3556399A1 (en) | 2016-12-19 | 2019-10-23 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
| MX2019007824A (es) | 2016-12-28 | 2019-09-09 | Japan Chem Res | Preparacion liofilizada. |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| KR20190013615A (ko) * | 2017-07-28 | 2019-02-11 | 한미약품 주식회사 | 이두로네이트 2-설파타제 결합체 |
| WO2019032955A1 (en) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| EP3894864A2 (en) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| US20250018015A1 (en) | 2021-07-23 | 2025-01-16 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| AR128003A1 (es) | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
-
2020
- 2020-04-03 AU AU2020252554A patent/AU2020252554B2/en active Active
- 2020-04-03 BR BR112021019520A patent/BR112021019520A2/pt unknown
- 2020-04-03 KR KR1020217035336A patent/KR20220004651A/ko active Pending
- 2020-04-03 EP EP20721359.6A patent/EP3947661A1/en active Pending
- 2020-04-03 MA MA71657A patent/MA71657A/fr unknown
- 2020-04-03 MX MX2021011612A patent/MX2021011612A/es unknown
- 2020-04-03 JP JP2021558657A patent/JP7715635B2/ja active Active
- 2020-04-03 CA CA3134538A patent/CA3134538A1/en active Pending
- 2020-04-03 US US17/600,527 patent/US12667606B2/en active Active
- 2020-04-03 WO PCT/US2020/026669 patent/WO2020206320A1/en not_active Ceased
- 2020-04-03 CN CN202080033104.6A patent/CN113785054A/zh active Pending
-
2025
- 2025-07-17 JP JP2025120522A patent/JP2025148550A/ja active Pending